Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206177 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2METPKMALDH1A1KMT2A | |
| SCHEMBL24585108 | 0.78 | GABRA5 (0.51) | PKMALDH1A1 | |
| SCHEMBL6238555 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2METPKMALDH1A1KMT2A | |
| SCHEMBL30723642 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2METALDH1A1KMT2AKDM4E | |
| SCHEMBL6238556 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2METPKMALDH1A1KMT2A | |
| SCHEMBL24585258 | 0.76 | NR1H4 (0.65) | — | |
| SCHEMBL24585975 | 0.75 | NR1H4 (0.47) | — | |
| SCHEMBL6079114 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2METALDH1A1KMT2AKDM4E | |
| SCHEMBL24585140 | 0.75 | NR1H4 (0.56) | — | |
| SCHEMBL16601177 | 0.74 | GABRG2 (0.46) | SMN1; SMN2PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4532487-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | Sanofi US Services Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119301115-A | Compounds for enhancing read-through of genes containing premature stop codons and methods of making and using the same | 赛诺菲美国服务公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | SMN1; SMN2 1143/4885MET 4533/4885PKM 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.